RecruitingPhase IIIEN original

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

NCT07388524Original on ClinicalTrials.gov ↗

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

•Rak płuca wczesnego stadium (IA3 lub IB), usunięty chirurgicznie w całości (bez pozostawienia komórek rakowych).
•Operacja usunięcia płata płuca lub większa. W niektórych przypadkach dopuszczalna jest mniejsza operacja, jeśli guz był mały.
•Wykonano odpowiednie badania węzłów chłonnych.
•W badaniu markera PD-L1 na komórkach rakowych uzyskano wynik 50% lub wyższy.
•Nie stwierdzono określonych mutacji genetycznych (EGFR, ALK) w komórkach raka.
•Pacjent został zakwalifikowany do badania od 3 do 11 tygodni po operacji.
•Pacjent doszedł do siebie po operacji.